GILEAD SCIENCES, INC. (GILD) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 11.02B USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 0.00 USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 5.05B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 1.95B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $11.02B | (m) | $0.00 | $5.05B | $1.95B | (m) |
| 2026-03-31 | (m) | $9.48B | (m) | $15.00M | $4.74B | $1.91B | (m) |
| 2025-12-31 | (m) | $11.81B | (m) | $68.00M | $4.91B | $1.77B | (m) |
| 2025-09-30 | (m) | $12.30B | (m) | $19.00M | $5.09B | $1.78B | (m) |
| 2025-06-30 | (m) | $11.19B | (m) | $69.00M | $4.78B | $1.82B | (m) |
| 2025-03-31 | (m) | $12.34B | (m) | (m) | $4.39B | $1.76B | (m) |
| 2024-12-31 | (m) | $12.00B | (m) | $0.00 | $4.42B | $1.71B | (m) |
| 2024-09-30 | (m) | $11.72B | (m) | $0.00 | $4.59B | $1.87B | (m) |
| 2024-06-30 | (m) | $10.78B | (m) | $0.00 | $4.66B | $2.03B | (m) |
| 2024-03-31 | (m) | $13.02B | (m) | $0.00 | $4.67B | $1.85B | (m) |
| 2023-12-31 | (m) | $11.28B | (m) | $1.18B | $4.66B | $1.79B | (m) |
| 2023-09-30 | (m) | $11.95B | (m) | $1.16B | $4.79B | $1.66B | (m) |
| 2023-06-30 | (m) | $13.96B | (m) | $963.00M | $4.23B | $1.63B | (m) |
| 2023-03-31 | (m) | $10.53B | (m) | $936.00M | $4.16B | $1.58B | (m) |
| 2022-12-31 | $11.16B | $11.24B | $5.41B | $973.00M | $4.78B | $1.51B | 0.99× |
| 2022-09-30 | (m) | $10.42B | (m) | $961.00M | $4.35B | $1.46B | (m) |
| 2022-06-30 | (m) | $9.22B | (m) | $924.00M | $4.12B | $1.49B | (m) |
| 2022-03-31 | (m) | $8.56B | (m) | $1.03B | $3.79B | $1.48B | (m) |
| 2021-12-31 | $11.01B | $11.61B | $5.34B | $1.18B | $4.49B | $1.62B | 0.95× |
| 2021-09-30 | (m) | $10.24B | (m) | $1.38B | $4.57B | $1.68B | (m) |
| 2021-06-30 | (m) | $10.21B | (m) | $1.63B | $4.15B | $1.77B | (m) |
| 2021-03-31 | (m) | $9.71B | (m) | $1.60B | $3.92B | $1.78B | (m) |
| 2020-12-31 | $12.30B | $11.40B | $6.00B | $1.41B | $4.89B | $1.68B | 1.08× |
| 2020-09-30 | (m) | $9.51B | (m) | $11.09B | $3.91B | $1.01B | (m) |
| 2020-06-30 | (m) | $10.56B | (m) | $12.17B | $3.19B | $1.05B | (m) |
| 2020-03-31 | (m) | $8.88B | (m) | $10.73B | $3.91B | $986.00M | (m) |
| 2019-12-31 | $27.93B | $9.76B | $11.63B | $12.72B | $3.58B | $922.00M | 2.86× |
| 2019-09-30 | (m) | $9.57B | (m) | $13.38B | $3.31B | $882.00M | (m) |
| 2019-06-30 | $30.58B | $8.96B | $11.24B | $15.94B | $3.40B | $884.00M | 3.41× |
| 2019-03-31 | $31.19B | $9.40B | $16.93B | $10.98B | $3.28B | $898.00M | 3.32× |
| 2018-12-31 | $33.42B | $10.61B | $17.94B | $12.15B | $3.33B | $814.00M | 3.15× |
| 2018-09-30 | $31.93B | $10.12B | $14.57B | $13.90B | $3.46B | $816.00M | 3.16× |
| 2018-06-30 | $29.46B | $10.91B | $13.23B | $12.68B | $3.54B | $859.00M | 2.70× |
| 2018-03-31 | $27.77B | $10.67B | $7.64B | $16.36B | $3.77B | $885.00M | 2.60× |
| 2017-12-31 | $29.36B | $11.63B | $7.59B | $17.92B | $3.85B | $801.00M | 2.52× |
| 2017-09-30 | $32.51B | $9.60B | $11.51B | $16.88B | $4.12B | $1.14B | 3.39× |
| 2017-06-30 | $25.57B | $8.49B | $8.71B | $12.38B | $4.48B | $1.41B | 3.01× |
| 2017-03-31 | $18.15B | $8.28B | $10.29B | $3.83B | $4.03B | $1.47B | 2.19× |
| 2016-12-31 | $16.41B | $9.22B | $8.23B | $3.67B | $4.51B | $1.59B | 1.78× |
| 2016-09-30 | $17.34B | $11.07B | $9.81B | $2.46B | $5.08B | $1.90B | 1.57× |
| 2016-06-30 | $14.50B | $10.44B | $6.49B | $2.27B | $5.75B | $1.86B | 1.39× |
| 2016-03-31 | $14.48B | $10.91B | $6.32B | $2.00B | $6.16B | $1.88B | 1.33× |
| 2015-12-31 | $20.46B | $9.89B | $12.85B | $1.76B | $5.85B | $1.96B | 2.07× |
| 2015-09-30 | $21.82B | $9.36B | $13.96B | $1.75B | $6.11B | $1.99B | 2.33× |
| 2015-06-30 | $13.94B | $8.93B | $7.42B | $1.19B | $5.33B | $2.04B | 1.56× |
| 2015-03-31 | $16.13B | $7.43B | $10.63B | $659.00M | $4.83B | $1.91B | 2.17× |
| 2014-12-31 | $14.76B | $5.76B | $10.03B | $101.00M | $4.63B | $1.39B | 2.56× |
| 2014-09-30 | $9.17B | $6.05B | $6.21B | $107.27M | $2.85B | $1.91B | 1.51× |
| 2014-06-30 | $12.24B | $6.23B | $8.73B | $68.55M | $3.44B | $2.07B | 1.96× |
| 2014-03-31 | $9.71B | $5.91B | $6.40B | $64.88M | $3.24B | $2.14B | 1.64× |
| 2013-12-31 | $4.23B | $6.33B | $2.11B | $18.76M | $2.10B | $2.06B | 0.67× |
| 2013-09-30 | $4.06B | $4.90B | $2.01B | $79.76M | $1.97B | $1.95B | 0.83× |
| 2013-06-30 | $4.18B | $4.94B | $2.20B | $85.19M | $1.90B | $1.94B | 0.85× |
| 2013-03-31 | $3.89B | $4.29B | $1.86B | $78.80M | $1.95B | $1.80B | 0.91× |
| 2012-12-31 | $3.61B | $4.27B | $1.80B | $58.56M | $1.75B | $1.74B | 0.85× |
| 2012-09-30 | $3.46B | $4.80B | $1.55B | $144.78M | $1.77B | $1.62B | 0.72× |
| 2012-06-30 | $3.41B | $4.99B | $1.63B | $82.04M | $1.70B | $1.60B | 0.68× |
| 2012-03-31 | $3.62B | $4.19B | $1.45B | $0.00 | $2.16B | $1.42B | 0.86× |
| 2011-12-31 | $11.85B | $2.51B | $9.88B | $16.49M | $1.95B | $1.39B | 4.71× |
| 2011-09-30 | $4.12B | $2.22B | $909.36M | $1.35B | $1.87B | $1.34B | 1.85× |
| 2011-06-30 | $4.21B | $2.31B | $905.78M | $1.36B | $1.94B | $1.32B | 1.82× |
| 2011-03-31 | $4.81B | $2.77B | $1.84B | $1.18B | $1.80B | $1.30B | 1.74× |
| 2010-12-31 | $3.72B | $2.46B | $907.88M | $1.19B | $1.62B | $1.20B | 1.51× |
| 2010-09-30 | $3.98B | $2.59B | $1.02B | $1.28B | $1.67B | $1.27B | 1.54× |
| 2010-06-30 | $3.48B | $3.11B | $1.48B | $518.29M | $1.48B | $1.36B | 1.12× |
| 2010-03-31 | $3.14B | $1.89B | $936.88M | $715.31M | $1.49B | $1.22B | 1.67× |
| 2009-12-31 | $3.05B | $1.87B | $1.27B | $384.02M | $1.39B | $1.05B | 1.63× |
| 2009-09-30 | $2.69B | $1.89B | $1.02B | $330.71M | $1.34B | $1.02B | 1.43× |
| 2009-06-30 | $2.49B | $1.78B | $1.04B | $203.39M | $1.24B | $969.97M | 1.40× |
| 2009-03-31 | (m) | (m) | $1.66B | (m) | (m) | (m) | (m) |
| 2008-12-31 | $2.81B | $1.22B | $1.46B | $330.76M | $1.02B | $927.87M | 2.30× |
| 2008-09-30 | (m) | (m) | $1.21B | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | $1.12B | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $968.09M | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | $816.01M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |